Blurbs

Kepler Capital Keeps a Sell Rating on Alcon (ALC)

In a report issued on May 11, David Evans from Kepler Capital maintained a Sell rating on Alcon (ALCResearch Report), with a price target of CHF64.00. The company’s shares closed last Thursday at $68.87.

According to TipRanks.com, Evans is ranked #3154 out of 7861 analysts.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $84.11.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $88.78 and a one-year low of $63.92. Currently, Alcon has an average volume of 868.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Alcon Inc. is a medical company which is specialized in eye care products. The company develops, manufactures, distributes, and sells technologies and devices for cataract, retinal, refractive surgery, as well as contact lenses and lens care products.

Read More on ALC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed